Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 1:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 95 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Insulin Secretion Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Beneficial Effect of Salicylates: Insulin Action, Secretion or Clearance?

NCT02007577
View directory record Official record
Conditions
Pre Diabetes, Insulin Resistant
Interventions
salsalate, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 60 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Sep 1, 2026, 1:55 PM EDT
Completed No phase listed Observational

Characterization of the Variability Of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Prediabetes

NCT01663207
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
Foundation for the National Institutes of Health
Other
Eligibility
30 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Sep 1, 2026, 1:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-response Study of Exendin-9,39 on Glucose Metabolism

NCT01218633
View directory record Official record
Conditions
Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1
Interventions
saline infusion, GLP-1-9,36 infusion, Exendin-9,39 at low dose, Exendin-9,39 at high dose
Drug
Lead sponsor
Adrian Vella
Other
Eligibility
20 Years to 45 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Sep 1, 2026, 1:55 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

NCT00992901
View directory record Official record
Conditions
Post Bariatricsurgery, Hypoglycemia
Interventions
Exendin-(9-39), Atropine, GLP-1 and GIP
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 1, 2026, 1:55 PM EDT
Completed No phase listed Observational

Side Effects of Antipsychotic Medications

NCT00363181
View directory record Official record
Conditions
Insulin Resistance, Metabolic Syndrome X, Schizophrenia and Disorders With Psychotic Features, Mood Disorders, Psychotic Disorders
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 66 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 21, 2021 · Synced Sep 1, 2026, 1:55 PM EDT
Completed No phase listed Observational

Insulin Secretory Defects in Pima Indians at High Risk for NIDDM

NCT00410800
View directory record Official record
Conditions
NIDDM
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2011
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 1, 2026, 1:55 PM EDT
Completed No phase listed Observational

Ivacaftor (Kalydeco) and Insulin in Cystic Fibrosis (CF)

NCT02039986
View directory record Official record
Conditions
Cystic Fibrosis Related Diabetes, Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Sep 1, 2026, 1:55 PM EDT
Withdrawn No phase listed Observational

Mechanisms of Diabetes Control After Weight Loss Surgery, Sub-study #1

NCT01930448
View directory record Official record
Conditions
Gastric Bypass Surgery, Gastric Banding, Type 2 Diabetes
Interventions
Not listed
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
20 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2015 · Synced Sep 1, 2026, 1:55 PM EDT
Withdrawn Not applicable Interventional

Insulin Resistance and Insulin Secretion

NCT00073294
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
diet
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
10 Years to 20 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Sep 1, 2026, 1:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Return of First-phase Insulin Secretion in Type 2 Diabetes is Associated With Depletion of Pancreas Lipid

NCT03430310
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Low Glycemic Diet, Control Diet
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
35 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Sep 1, 2026, 1:55 PM EDT
Completed Phase 3 Interventional Results available

SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2

NCT02592421
View directory record Official record
Conditions
Type II Diabetes Mellitus
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Sep 1, 2026, 1:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comprehensive Postpartum Screening Strategies for Women With Gestational Diabetes Mellitus (GDM)

NCT00849849
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Not listed
Lead sponsor
Woman's
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Sep 1, 2026, 1:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Incretin Action in Physiology and Diabetes

NCT02550548
View directory record Official record
Conditions
Insulin Secretion
Interventions
GIP infusion, GLP-1 infusion, Ex-9 infusion
Drug
Lead sponsor
David D'Alessio, M.D.
Other
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 1, 2026, 1:55 PM EDT
Completed No phase listed Observational

Study of Pregnancy Regulation of Insulin and Glucose

NCT02763267
View directory record Official record
Conditions
Gestational Diabetes Mellitus
Interventions
Oral glucose tolerance test
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Sep 1, 2026, 1:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Insulin Secretion in Diabetes Before and After Glycemic Control

NCT00469833
View directory record Official record
Conditions
Diabetes, Hyperglycemia
Interventions
insulin glargine
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
30 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 14, 2015 · Synced Sep 1, 2026, 1:55 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Effects of Xenin-25 on Insulin Secretion and Gastric Emptying in Humans With and Without a Complete Truncal Vagotomy

NCT01951716
View directory record Official record
Conditions
Does the Vagus Nerve Mediate the Effects of Xenin-25
Interventions
Graded Glucose Infusion with Placebo, Graded Glucose Infusion with GIP Alone, Graded Glucose Infusion with xenin-25 alone, Graded Glucose Infusion with GIP plus xenin-25, Meal Tolerance Test with Placebo, Meal Tolerance Test with xenin-25
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Sep 1, 2026, 1:55 PM EDT
Completed No phase listed Observational

Outpatient Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Type 2 Diabetes Mellitus

NCT02346344
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
Foundation for the National Institutes of Health
Other
Eligibility
30 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Tempe, Arizona • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Sep 1, 2026, 1:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Incretin Regulation of Insulin Secretion in Monogenic Diabetes

NCT01795144
View directory record Official record
Conditions
Monogenic Diabetes
Interventions
GLP-1, Exendin 9-39
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 89 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced Sep 1, 2026, 1:55 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Regulation of Insulin Secretion by the GLP-1 Receptor

NCT02844907
View directory record Official record
Conditions
Insulin Secretion
Interventions
Exendin (9-39), Dexamethasone, Hyperglycemic Clamp
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Sep 1, 2026, 1:55 PM EDT
Completed No phase listed Observational

Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Type 2 Diabetes Mellitus

NCT01663220
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
Foundation for the National Institutes of Health
Other
Eligibility
30 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2013 · Synced Sep 1, 2026, 1:55 PM EDT
Recruiting Not applicable Interventional

IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion

NCT07361874
View directory record Official record
Conditions
Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS), Subclinical Cushing's, Mild Autonomous Cortisol Excess
Interventions
Intervention 1: Adrenalectomy, Intervention 2: Semaglutide
Procedure · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 1, 2026, 1:55 PM EDT
Completed Phase 4 Interventional Results available

The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers

NCT00339833
View directory record Official record
Conditions
Type 2 Diabetes, Diabetes
Interventions
Salsalate, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Sep 1, 2026, 1:55 PM EDT
Not listed No phase listed Observational

Patterns and Natural History of Insulin Secretion in Islet Cell Transplant Recipients and Controls

NCT00018122
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 65 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 1, 2026, 1:55 PM EDT
Completed No phase listed Observational

Cross-Sectional and Longitudinal Studies of "Pre-Diabetes" in the Pima Indians

NCT00340132
View directory record Official record
Conditions
Weight Gain, Overweight, Insulin Resistance, Obesity, Diabetes Mellitus, Type 2
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 55 Years
Enrollment
1,759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1983
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 1, 2026, 1:55 PM EDT